Thrombolytics in acute ischaemic stroke: a guide to patient selection and optimum use.

Abstract

Intravenously administered alteplase (recombinant tissue plasminogen activator; rtPA) is the only medical treatment that has been approved for the management of acute ischaemic stroke. Although rtPA has demonstrated efficacy in improving outcomes of patients with a wide range of neurological impairments, it cannot be given with impunity. Thrombolytic… (More)

Topics

  • Presentations referencing similar topics